Portfoliotracker

Larimar Therapeutics, Inc.

LRMR · NASDAQGM · Healthcare Biotechnology 12/100 E

3,000 $
▼ −0,020 (−0,66 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:40
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score12 / 100 Market cap312 mil. $ P/E– Forward P/E-2,8 P/S– P/B2,4 EV/EBITDA– Dividend yield– FCF yield-50,08 % EPS-1,99 $ Net margin0,0 % Return on equity-139,6 % Beta0,70 Debt / equity0,04
52-week range 1,92 to 6,42
3-month average volume1,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Employees
71
Country
United States
Fiscal year end
31. 12.
Data since
19. 6. 2014

Explore further

Similar companies TARAORICFULCANNXOLMA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account